[1] M. Dougados, “Comorbidities in rheumatoid arthritis” Current Opinion in Rheumatology., vol. 28, no. 3, pp. 282–288, 2016. https://doi.org/10.1097/BOR.0000000000000267
[2] I. B. Mcinnes and G. Schett, “The Pathogenesis of Rheumatoid Arthritis” N. Engl. J. Med., vol. 365, pp. 2205–2219, 2011. https://doi.org/10.1056/NEJMra1004965
[3] L. Klareskog, L. Padyukov, J. Lorentzen and L. Alfredsson, “Mechanisms of Disease: genetic susceptibility and environmental triggers in the development of rheumatoid arthritis” Nature, vol. 2, no. 8, pp. 425–433, 2006. https://doi.org/10.1038/ncprheum0249
[4] S. Sardar and Å. Andersson, “Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development” Immunopharmacology and Immunotoxicology, pp. 1–12, 2016. https://doi.org/10.3109/08923973.2015.1125917
[5] A. Gaffo, K. Saag, and J. Curtis, “Treatment of rheumatoid arthritis” Am J Health-Syst Pharm., vol. 63, pp. 2451–2465, 2006. https://doi.org/10.2146/ajhp050514
[6] A. Reynolds, A. S. Koening, E. Bananis, A. Singh, “When is switching warranted among biologic therapies in rheumatoid arthritis?” Expert Review of Pharmacoeconomics & Outcomes Research, vol. 12, no. 3, pp. 319–333, 2012. https://dx.doi.org/10.1586/erp.12.27
[7] K. Yoshizaki, N. Nishimoto, M. Mihara and T. Kishimoto, “Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody” Springer Seminars in Immunopathology, vol. 20, pp. 247–259, 1998. https://doi.org/10.1007/bf00832010
[8] M. A. Karsdal, G. Schett, P. Emery et al., “IL-6 Receptor Inhibition Positively Modulates Bone Balance in Rheumatoid Arthritis Patients with an Inadequate Response to Anti-Tumor Necrosis Factor Therapy: Biochemical Marker Analysis of Bone Metabolism in the Tocilizumab RADIATE Study” Seminars in Arthritis and Rheumatism, vol. 42, no. 2, pp. 131–139, 2012. https://doi.org/10.1016/j.semarthrit.2012.01.004
[9] S. Finzel, S. Kraus, CP. Figueiredo et al., “Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis” Ann Rheum Dis, vol. 6, pp. 1186–1191, 2019. https://doi.org/10.1136/annrheumdis-2018-214894
[10] U. Sack, R. Kinne, T. Marx, P. Heppt, S. Bender and F. Emmrich, “Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis” Rheumatol. Int., vol. 13, pp. 45–51, 1993. https://doi.org/10.1007/BF00307733
[11] R. Madhok, A. Crilly, J. Watson, H. A. Capell and G. Royal, “Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity,” Ann Rheum Dis, vol. 52, pp. 232–234, 1993. https://doi.org/10.1136/ard.52.3.232
[12] J. M. Kremer, R. Blanco, M. Brzosko et al., “Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate: Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled Trial of Tocilizumab Safety and Prevention of Structural Joint Damage at one year,” Arthritis Rheum., vol. 63, no. 3, pp. 609–621, 2011. https://doi.org/10.1002/art.30158
[13] I. B. Mcinnes and G. Schett, “Cytokines in the pathogenesis of Rheumatoid Arthrits” Nat. Rev. Immunol., vol. 7, no. June, pp. 429–442, 2007. https://doi.org/10.1038/nri2094
[14] M. A. Karsdal, M. J. Nielsen, J. M. Sand et al., “Extracellular Matrix Remodeling: The Common Denominator in Connective Tissue Diseases” Assay Drug Dev. Technol., vol. 11, no. 2, pp. 70–92, 2013. https://doi.org/10.1089/adt.2012.474
[15] P. Lu, K. Takai, V. M. Weaver and Z. Werb, “Extracellular Matrix Degradation and Remodeling in Development and Disease” Cold Spring Harb. Perspect. Biol., vol. 3, 2011. https://doi.org/10.1101/cshperspect.a005058
[16] F. F. Mohammed, D. S. Smookler and R. Khokha, “Metalloproteinases, inflammation, and rheumatoid arthritis” Ann Rheum Dis, vol. 62, pp. 43–47, 2003. https://doi.org/10.1136/ard.62.suppl_2.ii43
[17] P. S. Burrage, K. S. Mix and C. E. Brinckerhoff, “Matrix metalloproteinases: Role in arthritis” Frontiers in Bioscience., vol. 11, pp. 529–543, 2006. https://doi.org/10.2741/1817
[18] A. S. Siebuhr, S. Sun, and I. Byrjalsen, “Suppression of active, but not total MMP-3, is associated with treatment response in a phase III clinical study of rheumatoid arthritis” Clinical and Experimental Rheumatology, vol. 36, pp. 94–101, 2018. https://www.clinexprheumatol.org/abstract.asp?a=11449
[19] M. A. Karsdal, K. Henriksen, D. J. Leeming et al., “Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development” Biomarkers, vol. 14, no. 3, pp. 181–202, 2009. https://doi.org/10.1080/13547500902777608
[20] A. C. Bay-Jensen, A. Platt, I. Byrjalsen, P. Vergnoud, C. Christiansen, and M. A. Karsdal, “Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study” Semin. Arthritis Rheum., vol. 43, no. 4, pp. 470–478, 2014. https://doi.org/10.1016/j.semarthrit.2013.07.008
[21] A. C. Bay-Jensen, A. Platt, A. S. Siebuhr, C. Christiansen, I. Byrjalsen and M. A. Karsdal, “Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study” Arthritis Research & Therapy, pp. 7–15, 2016. https://doi.org/10.1186/s13075-015-0913-x
[22] A. S. Siebuhr, A. C. Bay-Jeensen, D. J. Leeming et al., “Serological identification of fast progressors of structural damage with rheumatoid arthritis” Arthritis Research & Therapy, vol. 15, pp. 1–9, 2013. https://doi.org/10.1186/ar4266
[23] N. S. Gudmann, P. Junker, P. Juhl et al., “Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis” Clinical and Experimental Rheumatology, vol. 36, pp. 829–835, 2018. https://www.clinexprheumatol.org/article.asp?a=12293
[24] T. Kojima, Y. Yabe, A. Kaneko, Y. Hirano, H. Ishikawa and M. Hayashi, “Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis” Mod Rheumatol, vol. 23, pp. 977–985, 2013. https://doi.org/10.1007/s10165-012-0782-y
[25] P. Juhl, C. S. Thudium, N. S. Gudmann, M. A. Karsdal, and A. S. Siebuhr, “IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE Study” Clinical and Experimental Rheumatology, vol. 36, pp. 568–574, 2018. https://www.clinexprheumatol.org/article.asp?a=12085
[26] A. Bay-jensen, I. Byrjalsen, A. S. Siebuhr et al., “Serological Biomarkers of Joint Tissue Turnover Predict Tocilizumab Response at Baseline” J. Clin. Rheumatol., vol. 20, no. 6, pp. 332–335, 2014. https://doi.org/10.1097/RHU.0000000000000150
[27] G. Jones, A. Sebba, J. Gu et al., “Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study” Ann Rheum Dis, vol. 69, pp. 88–96, 2010. https://doi.org/10.1136/ard.2008.105197
[28] D. J. Leeming, Y. He, S. S. Veidal et al., “A novel marker for assessment of liver matrix remodeling: An enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M)” Biomarkers, vol. 16, no. 7, 2011. https://doi.org/10.3109/1354750X.2011.620628
[29] A. C. Bay-Jensen, Q. Liu, I. Byrjalsen et al., “Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM — Increased serum CIIM in subjects with severe radiographic osteoarthritis” Clinical Biochemistry, vol. 44, pp. 423–429, 2011. https://doi.org/10.1016/j.clinbiochem.2011.01.001
[30] N. Barascuk, S. S. Veidal, L. Larsen, D. V. Larsen, M. R. Larsen et al., ”A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen” Clinical Biochemistry, vol. 43, pp. 899-904, 2010. https://doi.org/10.1016/j.clinbiochem.2010.03.012
[31] M. A. Karsdal, F. Genovese, E. A. Madsen, T. Manon-Jensen, D. Schuppan, ”Collagen and tissue turnover as function of age: implications for fibrosis” Journal of Hepatology, vol. 64, no. 1, 2015. https://doi.org/10.1016/j.jhep.2015.08.014
[32] A. C. Bay-Jensen, S. Wichuk, I. Byrjalsen et al., “Circulating Protein Fragments of Cartilage and Connective Tissue Degradation Are Diagnostic and Prognostic Markers of Rheumatoid Arthritis and Ankylosing Spondylitis” PLoS One, vol. 8, no. 1, pp. 1–7, 2013. https://doi.org/10.1371/journal.pone.0054504
[33] T. Sokka “Radiographic scoring in rheumatoid arthritis: a short introduction to the methods” Bull NYU Hosp Jt Dis., vol. 66, no. 2, pp. 166-168, 2008. https://pubmed.ncbi.nlm.nih.gov/18537790/